AMBS LymPro Alzheimer’s Diagnostic Development

New Post Public Reply Private Reply Replies (0) Message Board
Compensated Post
shakerzzz

AMBS >>LymPro Alzheimer’s Diagnostic Development Strategy/to Present at BIO Business Forum April 23rd

2013-04-15 07:30 ET - News Release



SUNNYVALE, Calif. -- (Business Wire)

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis, today announced that Chief Executive Officer Gerald E. Commissiong is presenting at the BIO Business Forum in Chicago on Tuesday, April 23, at 10:45 a.m. Central. The presentation will be held in the Chicago Cubs Room in McCormick Place.

“The BIO Business Forum is an outstanding venue for presenting the Amarantus story to global constituencies, including health care professionals, potential business partners and investors,” said Mr. Commissiong. “In addition to our presentation, the Forum provides an opportunity for one-on-one business development meetings and interaction with industry leaders through the Forum Partnering program.”

The BIO Business Forum is part of the BIO International Conference, which is being held April 22-26, 2013 at McCormick Place. The conference is sponsored and hosted by the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

About Amarantus

Amarantus is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson’s disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property and licenses for the diagnosis of Parkinson’s disease and Alzheimer’s disease. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible progress of the MANF technology in testing for Parkinson’s disease, as well as statements about expectations, plans and prospects of the development of Amarantus’ diagnostic product candidates for Parkinson’s and Alzheimer’s disease. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks associated with development of therapeutic drug candidates, as well as the risks, uncertainties and assumptions relating to the development of Amarantus’ new product candidates, including those identified under “Risk Factors” in Amarantus’ most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.



Contacts:

Investor/Media Contact
LHA
Don Markley, Senior Vice President
310-691-7100
dmarkley@lhai.com


Source: Amarantus BioScience Holdings, Inc.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Piramal Pharma FY27 Q2 Results: Robust Growth & Optimism

Updated Category News Views 12

A Solid Performance from Piramal Pharma The numbers are in, and it's looking pretty good for Piramal Pharma Limited this time around. Their second quarter of fiscal year 2027 has seen some fireworks, and I'm not talking about some half-baked confetti deal. We're talking genuine growth and solid metrics here. Revenue and Profit Surge The headline? Revenue jumped a whopping...

Continue Reading
CORE Embraces Tech to Boost Organ Donation Efforts

Updated Category News Views 25

Innovation Meets Organ Donation Out of all the business moves you hear about, this one rings loud because it doesn’t just move the needle on a spreadsheet—it moves the needle on life or death. The Center for Organ Recovery & Education (CORE) is stepping into the future with a high-tech touch to enhance their lifesaving mission. Partnering with InVita Healthcare...

Continue Reading
Anti-Corruption Titans Gather for Key 20-Year IAACA Event

Updated Category News Views 47

Strength in Unity: A Global Anti-Corruption Gathering Here's a scene you don't stumble upon every day: corruption busters from all corners of the globe converging on Marrakech. The International Association of Anti-Corruption Authorities (IAACA) is rolling out the red carpet for its 20th-anniversary conference, a get-together poised to serve up not just pastries and...

Continue Reading
Chemours Faces Class Action over Misleading Guidance

Updated Category News Views 0

Legal Storm Brewing for Chemours Investors Seems like The Chemours Company, trading under NYSE:CC, is in some legal hot water right now. With the calendar quickly flipping towards December 7, investors are fronted with a crucial choice: step up to stake their claim as lead plaintiff in a securities fraud class action lawsuit, or watch from the sidelines. The Allegations...

Continue Reading
Investors Shaken by Better Home’s 28.5% Plunge

Updated Category News Views 32

Pull up a chair, because Better Home & Finance Holding Company (NASDAQ: BETR) just threw its investors into a frenzy. Mayhem hit when their stock nosedived 28.5% on a single day—May 7, 2026. Let’s untangle what happened and why every shareholder should circle November 20 on their calendar. Unpacking the Fall: A Dive Into Hard Truths So, between mid-March and early May...

Continue Reading
CTCA Tackles Trust Issues in $B-illion Card Market

Updated Category News Views 10

Gaps in a Booming Industry Trading cards might sound like kid stuff, but don’t be fooled—there's billions riding on paper and ink these days. Yet, a dark cloud hovers over the trading card scene, where questions of transparency and accountability loom large. Digital repacks and those dicey randomized packs have folks questioning what’s in the mix: Is it a safe bet...

Continue Reading
Beer B Que Music Festival: Hip-Hop, Dancehall & Brews

Updated Category News Views 67

A Melody and Brew-Infused South Florida Celebration Boy, if festivals were stocks, I'd have bought into the Beer B Que Music Festival years ago. This event, rolling into its seventh year, isn't just another line-up of artists—it feels like a genuine cultural reunion for folks in South Florida. You throw in some heavyweight names like Rick Ross and Kodak Black, plus the...

Continue Reading
Infosys Transforms Syngenta's Tech Core to Boost Agility

Updated Category News Views 76

Unpacking the Syngenta-Infosys Transformation Forget your run-of-the-mill tech upgrade; Infosys has just spearheaded a massive transformation for Syngenta, delivering a new global SAP S/4HANA setup that’s set to turbocharge their Crop Protection business. We’re talking about more than just another software upgrade here—this is a sweeping overhaul affecting 10,000...

Continue Reading
Billd's Flex Line: Game-Changer for Subcontractor Credit

Updated Category News Views 77

Billd's Bold Move Across America Forget piecemeal rollouts; Billd's taking their latest brainchild, Flex Line, right into the heart of America's subcontractor landscape. This isn't some flash-in-the-pan financial offering, either—it's a heavy-hitter poised to shake up the way subcontractors wrangle their working capital. We're talking about a line of credit that's as...

Continue Reading
Americans' Faith in Democracy Hits New Lows

Updated Category News Views 73

Polarization Beyond Politics: A National Reckoning When you catch wind of a report like this one, it's enough to make you feel like the fabric of democracy is unraveling right before our eyes. We're staring at a national identity crisis, folks, and it's got nothing to do with whether you're waving a red or blue flag. This ain't about party lines; it's about a bigger,...

Continue Reading

Top 5 Most Recently Viewed Articles

Teamsters Local 107 Strikes for Job Security & Fair Contract

Updated Category News Views 36

Fight for Job Security and Family Futures The winds of change are blowing through Philadelphia as the Teamsters Local 107 scaffolders are locked in a battle at BrandSafway. Known for grit and loyalty, these warehouse workers and drivers have rolled the dice for fair labor practices, launching a strike against what they're calling the raw deals from their employer. From...

Continue Reading
Blink Charging's New Partnership Pivots EV Charging Experience

Updated Category News Views 100

Understanding Blink Charging's Latest Developments In the rapidly evolving electric vehicle (EV) market, infrastructure challenges remain critical. Blink Charging Co. (NASDAQ: BLNK) is stepping up to tackle these hurdles with a promising new partnership. The Game-Changing Collaboration with Presto Blink Charging has recently established a collaboration with Presto, a...

Continue Reading
HeartSciences' Latest Developments: Key Advisors Join Board

Updated Category News Views 126

HeartSciences Welcomes New Members to Scientific Advisory Board HeartSciences Inc. (NASDAQ: HSCS) is making significant strides in the field of cardiac healthcare by announcing new appointments to its Scientific Advisory Board. This AI-driven medical technology company is dedicated to revolutionizing ECG screenings, paving the way for early heart disease detection. By...

Continue Reading
Scotiabank Boosts TIM S.A. Rating to Reflect Growth Prospects

Updated Category News Views 79

Scotiabank's Positive Outlook for TIM S.A. Scotiabank has recently upgraded its outlook for TIM S.A. (NYSE:TIMB), moving its stock rating from Sector Perform to Sector Outperform. This significant change reflects Scotiabank's confidence in TIM S.A.'s growth potential over the next year. They've also raised the price target for the stock to $24.80, up from $17.50,...

Continue Reading
Vinitaly.USA: A Celebration of Italian Wines Advanced Growth

Updated Category News Views 398

Vinitaly.USA 2025 Set to Showcase Italian Winemaking Excellence Prepare for an exciting gathering of nearly 250 Italian wineries and consortia, symbolizing a robust $7 billion in turnover, as they come together for the second edition of Vinitaly.USA at Navy Pier. This event, occurring over two days, underscores the unwavering commitment of Italian wine producers to the...

Continue Reading